Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
radelumin
- Development stage
- Phase 3
- Lead developer
- ABX
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Radelumin is a radiopharmaceutical diagnostic agent containing the active substance [18F]PSMA-1007. It is used in positron emission tomography (PET) imaging to detect prostate-specific membrane antigen (PSMA)-positive lesions in adult patients with prostate cancer. Its primary indications are for the primary staging of high-risk prostate cancer prior to curative therapy and for detecting suspected recurrence of prostate cancer in patients with rising serum PSA levels after initial treatment. The mechanism involves targeting PSMA-expressing cells, allowing precise visualization of tumor sites via PET scanning. Radelumin is administered intravenously and is intended strictly for diagnostic use only[1][2][3][4][5].
- Brand names
- Radelumin
- Other names
- 18F-PSMA-1007[18F]PSMA-1007Radelumin®
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on radelumin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on radelumin.